Cargando…

Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice

Background: The efficacy of nivolumab and atezolizumab in advanced pre-treated NSCLC was documented in prospective trials. We aim to confirm the benefits and indicate predictive factors for immunotherapy in daily practice. Methods: This study was a retrospective analysis. The median PFS and OS were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knetki-Wróblewska, Magdalena, Tabor, Sylwia, Piórek, Aleksandra, Płużański, Adam, Winiarczyk, Kinga, Zaborowska-Szmit, Magdalena, Zajda, Katarzyna, Kowalski, Dariusz M., Krzakowski, Maciej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053214/ https://www.ncbi.nlm.nih.gov/pubmed/36983409 http://dx.doi.org/10.3390/jcm12062409

Ejemplares similares

A case of adenoid cystic carcinoma of trachea: treatment complications and radiotherapy role
por: Piórek, Aleksandra, et al.
Publicado: (2021)

Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung Cancer after Chemoradiotherapy
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2023)

Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022)

Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2020)

Performance-Status Deterioration during Sequential Chemo-Radiotherapy as a Predictive Factor in Locally Advanced Non-Small Cell Lung Cancer
por: Olszyna-Serementa, Marta, et al.
Publicado: (2023)

Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2020)

Do We Need TNM for Tracheal Cancers? Analysis of a Large Retrospective Series of Tracheal Tumors
por: Piórek, Aleksandra, et al.
Publicado: (2022)

Crizotinib in the treatment of non-small-cell lung carcinoma
por: Płużański, Adam, et al.
Publicado: (2013)

Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022)

Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2021)

The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients
por: Kucharczyk, Tomasz, et al.
Publicado: (2015)

Thymic epithelial tumors: Do we know all the prognostic factors?
por: Knetki‐Wróblewska, Magdalena, et al.
Publicado: (2021)

Solitary fibrous tumour along with non-small-cell lung cancer and Doege-Potter syndrome
por: Piórek, Aleksandra, et al.
Publicado: (2019)

Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients
por: Pluzanski, Adam, et al.
Publicado: (2020)

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
por: Krawczyk, Paweł, et al.
Publicado: (2014)

A thymoma or not a thymoma—that is the question: a case report
por: Szolkowska, Malgorzata, et al.
Publicado: (2021)

Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?
por: Zaborowska, Magdalena, et al.
Publicado: (2012)

Nivolumab treatment followed by atezolizumab induced encephalitis and neuropathy with antiganglioside antibodies
por: Watanabe, Shohei, et al.
Publicado: (2021)

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab
por: Niewada, Maciej, et al.
Publicado: (2023)

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
por: Franchi, Matteo, et al.
Publicado: (2022)

Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic Carcinomas
por: Szpechcinski, Adam, et al.
Publicado: (2022)

Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study
por: Pluzanski, Adam, et al.
Publicado: (2023)

Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer
por: Ramagopalan, Sreeram, et al.
Publicado: (2021)

Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland
por: Kowalski, Dariusz M., et al.
Publicado: (2012)

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
por: Alonso-García, Miriam, et al.
Publicado: (2022)

Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition
por: Swed, Brandon, et al.
Publicado: (2021)

Real-World Outcomes of Nivolumab, Pembrolizumab, and Atezolizumab Treatment Efficacy in Korean Veterans with Stage IV Non-Small-Cell Lung Cancer
por: Ham, Ahrong, et al.
Publicado: (2023)

RET Proto-Oncogene—Not Such an Obvious Starting Point in Cancer Therapy
por: Kucharczyk, Tomasz, et al.
Publicado: (2022)

Structural Comparison of Sulfonamide-Based Derivatives That Can Improve Anti-Coagulation Properties of Metformin
por: Zajda, Agnieszka, et al.
Publicado: (2022)

PD-L1 detection using (89)Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response
por: Vento, Joseph, et al.
Publicado: (2019)

A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
por: Kim, Hyung Jun, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

The Impact of Gelatin on the Pharmaceutical Characteristics of Fucoidan Microspheres with Posaconazole
por: Szekalska, Marta, et al.
Publicado: (2021)

Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2021)

Two Cases of Atezolizumab-Induced Hypophysitis
por: Kanie, Keitaro, et al.
Publicado: (2017)

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
por: Lambert, Nicolas, et al.
Publicado: (2022)

Effective Techniques for Multimodal Data Fusion: A Comparative Analysis
por: Pawłowski, Maciej, et al.
Publicado: (2023)

The development of recycling methods for bio-based materials – A challenge in the implementation of a circular economy: A review
por: Zaborowska, Magdalena, et al.
Publicado: (2022)

A clinical variable‐based nomogram could predict the survival for advanced NSCLC patients receiving second‐line atezolizumab
por: Shang, Xiaoling, et al.
Publicado: (2021)

Targeted Delivery of Cisplatin by Gold Nanoparticles: The Influence of Nanocarrier Surface Modification Type on the Efficiency of Drug Binding Examined by CE-ICP-MS/MS
por: Wróblewska, Anna M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p6v0iv5m69e2apvrb864amqeg6